Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center, Randomized, Double-Blind, Parallel, Placebo-Controlled, Phase III Clinical Study to Evaluate Efficacy and Safety of SP-8203 (Otaplimastat) in Patients With Acute Ischemic Stroke Requiring Thrombolytic Therapy as Standard of Care

NCT06660719 is registered in ClinicalTrials.gov with Shin Poong Pharmaceutical Co. Ltd. as lead sponsor.

NCT NCT06660719
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06660719 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center, Randomized, Double-Blind, Parallel, Placebo-Controlled, Phase III Clinical Study to Evaluate Efficacy and Safety of SP-8203 (Otaplimastat) in Patients With Acute Ischemic Stroke Requiring Thrombolytic Therapy as Standard of Care
Lead sponsor
Shin Poong Pharmaceutical Co. Ltd.
Phase
Phase 3
Overall status
Recruiting
Start date
February 14, 2025
Completion date
March 30, 2027
Enrollment
852 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

ischemic stroke